Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine

Fig. 2

Forest plot of pair-wise meta-analysis of primary endpoints: impact of the erdosteine, carbocysteine, and NAC on the risk of AECOPD vs. placebo (a); sensitivity analysis performed by excluding the studies that introduced significant heterogeneity in the overall effect estimate (b); publication bias assessment via funnel plot (c) and Egger’s test (d); ranking plot resulting from the network meta-analysis in which treatments were plotted on X-axis according to SUCRA (score of 1 being the most effective) and on Y-axis according to the rank of being the best treatment (score of 1 being the most effective) (e). #P < 0.1, *P < 0.05, **P < 0.01, and ***P < 0.001. AECOPD acute exacerbation of COPD, COPD chronic obstructive pulmonary disease, NA not available, NAC N-acetylcysteine, SND standard normal deviate, SUCRA surface under the cumulative ranking curve

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us